No results for ‘’
Lyka Labs Ltd
₹67.38
(3.83%)
Tue, 23 Jun 2026, 04:23 am
Health Technology
Pharmaceuticals: Other
24.5KLyka Labs EV/EBITDA Ratio
| Particulars | 2005 | 2006 | 2007 | 2009 | 2010 | 2011 | 2012 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 15.43 | 0 | 29.30 | 0 | 0 | 0 | 47.67 | 0 | 0 | 0 | 0 | 0 | 9.98 | 0 | 0 | 44.83 |
| Price to book ratio | 2.16 | 1.11 | 1.03 | 0.84 | 0.67 | 0.33 | 0.30 | 0.77 | 4.05 | 3.19 | 2.61 | 1.60 | 0 | 0 | 29.17 | 7.07 | 5.14 | 3.48 |
| Price to sales ratio | 1.24 | 0.58 | 0.72 | 0.49 | 0.49 | 0.22 | 0.16 | 0.44 | 1.35 | 1.12 | 2.02 | 1.02 | 0.60 | 0.88 | 2.02 | 3.29 | 3.18 | 2.61 |
| Price to cash flow ratio | 2.75 | 0 | 0 | 0 | 0 | 0 | 0 | 0.58 | 0 | 8.99 | 67.68 | 3.51 | 0 | 24.60 | 6.75 | 0 | 0 | 0 |
| Enterprise value | 116Cr | 83.58Cr | 117Cr | 154Cr | 180Cr | 151Cr | 169Cr | 190Cr | 283Cr | 248Cr | 232Cr | 166Cr | 168Cr | 231Cr | 503Cr | 365Cr | 402Cr | 397Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 15.83 | 18.82 | 9.66 | 23.89 | 12.76 | 135.51 | 16.03 | 12.13 | 0 | 0 | 0 | 12.74 | 5.23 | 23.16 | 28.14 | 23.46 |
| Debt to equity ratio | 2.23 | 1.27 | 0.70 | 1.27 | 1.12 | 1.74 | 2.30 | 3.08 | 2.57 | 3.33 | 2.28 | 2.24 | 0 | 0 | 9.78 | 1.65 | 0.86 | 0.38 |
| Return on equity % | 0 | -30.25 | 6.75 | 0 | 2.61 | -0.55 | -1.02 | 0 | 7.75 | -13.87 | -39.63 | -12 | -423.07 | 0 | 0 | -44.95 | -4.38 | 9.33 |
Lyka Labs Ltd Enterprise Value to EBITDA Ratio
The Lyka Labs Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Lyka Labs Ltd's valuation, profitability, and overall financial performance. Tracking the Lyka Labs Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Lyka Labs Ltd (NSE: LYKALABS, BSE: 500259) is currently trading at ₹67.38, with a market capitalization of ₹242.37Cr. As a leading company in the Health technology sector and Pharmaceuticals: other industry, monitoring the Lyka Labs Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.
Lyka Labs Ltd Enterprise Value to EBITDA Ratio Current Value
The current Lyka Labs Ltd Enterprise Value to EBITDA Ratio stands at 23.46.
The Lyka Labs Ltd Enterprise Value to EBITDA Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Lyka Labs Ltd Enterprise Value to EBITDA Ratio Historical Trend
The Lyka Labs Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:
- 2024: 23.46
- 2023: 28.14
- 2022: 23.16
- 2021: 5.23
- 2020: 12.74
The decline in Lyka Labs Ltd Enterprise Value to EBITDA Ratio indicates improving financial efficiency or better earnings growth.
What Lyka Labs Ltd Enterprise Value to EBITDA Ratio Indicates for Investors
The Lyka Labs Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Lyka Labs Ltd.
Lyka Labs Ltd Enterprise Value to EBITDA Ratio Analysis Summary
The Lyka Labs Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Lyka Labs Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Lyka Labs Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.